Pfizer has announced that is to invest over €1.2bn at its Grange Castle facility. The investment will see a new facility built on the site premises and will double the capacity for biological drug substance manufacturing at the facility and create hundreds of new jobs at the facility.

Pfizer first established operations in Ireland in Ringaskiddy 1969, growing and has continuously invested in its facilities over the past 53 years. They presently employ some 5,000 people in Ireland.

Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer: “We are very pleased about today’s announcement, as it significantly strengthens our operations in Ireland, where we have three high-performing and strategic manufacturing sites. Grange Castle has played a critical role in our global Covid-19 vaccine network, and this investment for non-Covid licensed and pipeline products will help to further expand the site’s broad and robust capabilities.”

Tánaiste Leo Varadkar TD said: ‘’The pharma sector is such an important part of the Irish economy and the commitment shown by Pfizer to further expand its business here is great news. The work undertaken at their facilities across Ireland saves and improves the lives of people all over the world.  I am very pleased that their presence in Dublin, and indeed in Ireland, continues to go from strength to strength.’’

IDA Ireland Interim CEO Mary Buckley said: ‘’Pfizer has had a presence in Ireland for over 50 years and this major additional investment, adding further drug substance capacity to its already substantial Irish operations and jobs, underscores the strategic importance of Ireland in Pfizer’s global operations. It is proof of the company’s future commitment to Ireland and testament to Ireland’s continued attractiveness as a location for investment.’

Follow Irish building magazine on LinkedIn for the latest news